| 000 | 01888 a2200577 4500 | ||
|---|---|---|---|
| 005 | 20250516171530.0 | ||
| 264 | 0 | _c20140403 | |
| 008 | 201404s 0 0 eng d | ||
| 022 | _a1532-6535 | ||
| 024 | 7 |
_a10.1038/clpt.2013.187 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVieira, Md L T | |
| 245 | 0 | 0 |
_aEvaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. _h[electronic resource] |
| 260 |
_bClinical pharmacology and therapeutics _cFeb 2014 |
||
| 300 |
_a189-98 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A Inhibitors |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aDrugs, Investigational _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aMidazolam _xblood |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aRisk Assessment |
| 700 | 1 | _aKirby, B | |
| 700 | 1 | _aRagueneau-Majlessi, I | |
| 700 | 1 | _aGaletin, A | |
| 700 | 1 | _aChien, J Y L | |
| 700 | 1 | _aEinolf, H J | |
| 700 | 1 | _aFahmi, O A | |
| 700 | 1 | _aFischer, V | |
| 700 | 1 | _aFretland, A | |
| 700 | 1 | _aGrime, K | |
| 700 | 1 | _aHall, S D | |
| 700 | 1 | _aHiggs, R | |
| 700 | 1 | _aPlowchalk, D | |
| 700 | 1 | _aRiley, R | |
| 700 | 1 | _aSeibert, E | |
| 700 | 1 | _aSkordos, K | |
| 700 | 1 | _aSnoeys, J | |
| 700 | 1 | _aVenkatakrishnan, K | |
| 700 | 1 | _aWaterhouse, T | |
| 700 | 1 | _aObach, R S | |
| 700 | 1 | _aBerglund, E G | |
| 700 | 1 | _aZhang, L | |
| 700 | 1 | _aZhao, P | |
| 700 | 1 | _aReynolds, K S | |
| 700 | 1 | _aHuang, S-M | |
| 773 | 0 |
_tClinical pharmacology and therapeutics _gvol. 95 _gno. 2 _gp. 189-98 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/clpt.2013.187 _zAvailable from publisher's website |
| 999 |
_c23099984 _d23099984 |
||